Cephalon Acquires Cancer Drug Trisenox® from Cell Therapeutics
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 61 (Table of Contents)
Published: 5 Jul-2005
DOI: 10.3833/pdr.v2005.i61.658 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Cephalon has signed an asset acquisition agreement with Cell Therapeutics and its subsidiary CTI Technologies for Trisenox® (arsenic trioxide) injection...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS